Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trichomylin Phase 1 SAD/MAD Study
NCT04867057Phase 1Completed
- Sponsor
- ZYUS Life Sciences Corporation
- Start
- Apr 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Trichomylin in osteoarthritis (OA) (4 arms), sponsored by ZYUS Life Sciences Corporation. Primary endpoint: Percentage and severity of unexpected Serious Adverse Events at 1 year. Started Apr 2021; status: completed.
02
Drugs
Trichomylin
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04867057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04867057.